Genetic polymorphisms in key hypoxia-regulated downstream molecules and phenotypic correlation in prostate cancer

BMC Urology

Table 4 Expression of proteins from hypoxia pathways in prostate cancer patients, by Gleason grade and PSA value

	Gleason grade (n = 38)			PSA at diagnosis (n = 36)
	<7	≥7	P	<10	≥10	P
VEGFR2 H-score^a	30.9 ± 24.7	60.1 ± 17.9	0.099	30.2 ± 1.2	80.0 ± 33.5	0.085
LOX immunoreactivity score^a	10.2 ± 1.6	7.6 ± 1.1	0.184	9.2 ± 1.1	6.6 ± 1.8	0.242
HIF-1α expression^b
Negative	6 (0.50)	19 (0.73)		17 (0.65)	8 (0.80)	0.335^c
Positive	6 (0.50)	7 (0.27)	0.163	9 (0.35)	2 (0.20)	0.335^c
CAIX expression^b
Negative	10 (0.83)	15 (0.58)		19 (0.73)	5 (0.50)
Positive	2 (0.17)	11 (0.42)	0.117 ^c	7 (0.27)	5 (0.50)	0.078

PSA prostate specific antigen, VEGFR2 vascular endothelial growth factor receptor 2, LOX lysyl oxidase, HIF1a hypoxia inducible factor 1 alpha, CAIX carbonic anhydrase IX
^a Kruskal Wallis and Mann–Whitney U tests for VEGFR2 H-score in epithelial cells; ^b Chi-square test.^c Fisher exact test

ISSN: 1471-2490